JP2015503560A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503560A5
JP2015503560A5 JP2014550335A JP2014550335A JP2015503560A5 JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5 JP 2014550335 A JP2014550335 A JP 2014550335A JP 2014550335 A JP2014550335 A JP 2014550335A JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5
Authority
JP
Japan
Prior art keywords
composition
solid dispersion
hcv
solid
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550335A
Other languages
English (en)
Japanese (ja)
Other versions
JP5781706B2 (ja
JP2015503560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/070349 external-priority patent/WO2013101550A1/en
Publication of JP2015503560A publication Critical patent/JP2015503560A/ja
Publication of JP2015503560A5 publication Critical patent/JP2015503560A5/ja
Application granted granted Critical
Publication of JP5781706B2 publication Critical patent/JP5781706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550335A 2011-12-29 2012-12-18 Ｈｃｖ阻害剤を含む固体組成物 Active JP5781706B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161581146P 2011-12-29 2011-12-29
US61/581,146 2011-12-29
US201261645696P 2012-05-11 2012-05-11
US61/645,696 2012-05-11
PCT/US2012/070349 WO2013101550A1 (en) 2011-12-29 2012-12-18 Solid compositions comprising an hcv inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015140513A Division JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Publications (3)

Publication Number Publication Date
JP2015503560A JP2015503560A (ja) 2015-02-02
JP2015503560A5 true JP2015503560A5 (enExample) 2015-03-12
JP5781706B2 JP5781706B2 (ja) 2015-09-24

Family

ID=47470243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014550335A Active JP5781706B2 (ja) 2011-12-29 2012-12-18 Ｈｃｖ阻害剤を含む固体組成物
JP2015140513A Pending JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015140513A Pending JP2015227352A (ja) 2011-12-29 2015-07-14 Ｈｃｖ阻害剤を含む固体組成物

Country Status (9)

Country Link
US (1) US20130172239A1 (enExample)
EP (2) EP2797586A1 (enExample)
JP (2) JP5781706B2 (enExample)
CN (1) CN104010631B (enExample)
CA (1) CA2857339C (enExample)
DE (1) DE212012000197U1 (enExample)
HK (1) HK1201186A1 (enExample)
MX (1) MX2014008008A (enExample)
WO (1) WO2013101550A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150119317A1 (en) * 2012-05-07 2015-04-30 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
MY172166A (en) * 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CA2905423A1 (en) * 2013-03-15 2014-09-25 Achillion Pharmaceuticals, Inc. Sovaprevir tablets
US9732076B2 (en) 2013-03-15 2017-08-15 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015119919A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Pharmaceutical composition of selective hcv ns3/4a inhibitors
WO2015119924A2 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
JP2017512811A (ja) * 2014-04-03 2017-05-25 サンド・アクチエンゲゼルシヤフト 非晶質ソホスブビルを含む固体組成物
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
WO2016075588A1 (en) * 2014-11-11 2016-05-19 Sun Pharmaceutical Industries Limited Stable amorphous daclatasvir dihydrochloride
JP2018505201A (ja) * 2015-02-13 2018-02-22 サンド・アクチエンゲゼルシヤフト レジパスビルおよびソホスブビルを含む医薬組成物
WO2016145269A1 (en) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
WO2017021904A1 (en) * 2015-08-03 2017-02-09 Laurus Labs Private Limited Daclatasvir free base and process for the preparation thereof
WO2017023715A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20180228828A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023714A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023713A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017060374A1 (en) 2015-10-07 2017-04-13 Sandoz Ag Solid pharmaceutical composition comprising amorphous sofosbuvir
WO2017072714A1 (en) 2015-10-30 2017-05-04 Lupin Limited Stable ledipasvir premix and process of preparation thereof
JOP20170127A1 (ar) * 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
CN109862884A (zh) 2016-08-12 2019-06-07 桑多斯股份公司 包含无定形索非布韦的固体药物组合物
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
CN106727516A (zh) * 2017-01-10 2017-05-31 山东省立医院 一种治疗丙型肝炎的药物组合物
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
US11378965B2 (en) 2018-11-15 2022-07-05 Toyota Research Institute, Inc. Systems and methods for controlling a vehicle based on determined complexity of contextual environment
CN113209087B (zh) * 2020-02-05 2023-11-07 歌礼药业（浙江）有限公司 一种抑制冠状病毒的药物组合物及其用途
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
KR102842201B1 (ko) * 2023-09-19 2025-08-06 한국해양과학기술원 Lng 추진 선박용 이산화탄소 액화 시스템 및 방법
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007433A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
KR20100090689A (ko) * 2007-10-19 2010-08-16 애보트 게엠베하 운트 콤파니 카게 Ｎ―아릴 우레아계 화합물을 함유하는 고체 분산액 생성물
WO2010017432A1 (en) * 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
LT2401272T (lt) * 2009-02-27 2017-03-27 Janssen Pharmaceuticals, Inc. Hcv makrociklinio slopiklio amorfinė druska
KR20180028070A (ko) * 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) * 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑

Similar Documents

Publication Publication Date Title
JP2015503560A5 (enExample)
ECSP13012382A (es) Composiciones sólidas
JP2016521119A5 (enExample)
JP2013032389A5 (enExample)
HK1201186A1 (en) Solid compositions comprising an hcv inhibitor
JP2013530958A5 (enExample)
JP2015507065A5 (enExample)
CL2013001120A1 (es) Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune.
JP2011105738A5 (enExample)
JP2011527299A5 (enExample)
JP2012144574A5 (enExample)
JP2010536766A5 (enExample)
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
JP2013542247A5 (enExample)
JP2008533007A5 (enExample)
HK1203514A1 (en) D-amino acid compounds for liver disease
JP2011518833A5 (enExample)
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
JP2014523459A5 (enExample)
JP2011518842A5 (enExample)
JP2012199532A5 (enExample)
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
EP2749582A4 (en) FLUOROUS COPOLYMER AND SURFACE MODIFICATOR THEREFOR AS ACTIVE SUBSTANCE
JP2008517059A5 (enExample)